Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

From the genetics of ankylosing spondylitis to new biology and drug target discovery

Journal article

ZAAROUR N. et al, (2021), Frontiers in immunology

Functional Genomic Analysis of a RUNX3 Polymorphism Associated with Ankylosing Spondylitis.

Journal article

Vecellio M. et al, (2020), Arthritis rheumatol

From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis

Journal article

Fang H. et al, (2020), The lancet rheumatology, 2, e50 - e62

GM-CSF Primes Proinflammatory Monocyte Responses in Ankylosing Spondylitis.

Journal article

Shi H. et al, (2020), Front immunol, 11

A genetics-led approach defines the drug target landscape of 30 immune-related traits.

Journal article

Fang H. et al, (2019), Nat genet, 51, 1082 - 1091

Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases.

Journal article

Hammitzsch A. et al, (2018), Sci rep, 8

Genetic Architecture of Adaptive Immune System Identifies Key Immune Regulators.

Journal article

Lagou V. et al, (2018), Cell rep, 25, 798 - 810.e6

Is Behçet's disease a 'class 1-opathy'? The role of HLA-B*51 in the pathogenesis of Behçet's disease.

Journal article

Giza M. et al, (2018), Clin exp immunol, 191, 11 - 18

A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis.

Journal article

Schwerd T. et al, (2017), J exp med, 214, 2547 - 2562

miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis.

Journal article

Chen L. et al, (2017), Ann rheum dis, 76, 620 - 625

Load More